Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
GHRP-6
Also known as: Growth Hormone Releasing Peptide 6, Growth Hormone Releasing Hexapeptide, SKF-110679
GHRP-6 is one of the earliest synthetic growth hormone releasing peptides, a hexapeptide that potently stimulates GH secretion through the ghrelin receptor. It is well-characterized in the literature and produces robust GH release but is accompanied by a strong appetite-stimulating effect. It was pivotal in the discovery of the ghrelin receptor signaling pathway.
Risk Level
Medium RiskDifficulty
Intermediate| CAS Number | 87616-84-0 |
| Molecular Formula | C46H56N12O6 |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
GHRP-6 acts as a potent ghrelin mimetic at the GHS-R1a receptor, triggering GH release from pituitary somatotrophs via intracellular calcium mobilization. It strongly stimulates appetite through hypothalamic ghrelin signaling, making it the most orexigenic of the common GHRPs. It raises cortisol and prolactin levels more than Ipamorelin but similarly to GHRP-2, and synergizes with GHRH analogs for amplified GH output.
Dosing Research
Typical dosing is 100-300 mcg subcutaneously 2-3 times daily on an empty stomach. The saturation dose is approximately 100 mcg per injection. Often used in combination with GHRH analogs like CJC-1295 without DAC.
Side Effects & Risks
Intense hunger shortly after injection is the most prominent side effect. Cortisol and prolactin elevations occur, particularly at higher doses. Water retention, joint pain, and tingling in the hands and feet are commonly reported. May increase gastric motility and cause stomach discomfort.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.